Source: European Medicines Agency (EU) Revision Year: 2024 Publisher: YES Pharmaceutical Development Services GmbH, Basler Strasse 7, 61352 Bad Homburg, Germany
Mevlyq 0.44 mg/mL solution for injection.
| Pharmaceutical Form |
|---|
|
Solution for injection (injection). Clear, colourless aqueous solution with a pH of 6.0-9.0. |
Each mL contains 0.5 mg eribulin mesilate equivalent to 0.44 mg eribulin.
Each 2 mL vial contains eribulin mesilate equivalent to 0.88 mg eribulin.
Excipient with known effect: Each mL solution for injection contains 40 mg ethanol.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Eribulin mesylate |
Eribulin is a microtubule dynamics inhibitor belonging to the halichondrin class of antineoplastic agents. It is a structurally simplified synthetic analogue of halichondrin B, a natural product isolated from the marine sponge Halichondria okadai. |
| List of Excipients |
|---|
|
Ethanol anhydrous |
4 mL type I colourless glass vial, with teflon-coated, butyl rubber stopper and flip-off aluminium over seal, containing 2 mL of solution.
The pack size is 1 vial.
YES Pharmaceutical Development Services GmbH, Basler Strasse 7, 61352 Bad Homburg, Germany
EU/1/23/1789/001
| Drug | Countries | |
|---|---|---|
| MEVLYQ | Estonia, Croatia, Ireland, Italy, Lithuania |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
